Nls pharmaceutics announces compliance with nasdaq bid price requirement

Zurich, switzerland / accesswire / january 12, 2023 / nls pharmaceutics ltd. (nasdaq:nlsp, nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it received a notification letter from the nasdaq listing qualifications staff of the nasdaq stock market llc ("nasdaq") notifying the company that it has regained compliance with the nasdaq's minimum bid price requirement.
NLSP Ratings Summary
NLSP Quant Ranking